Key terms
About PYPD
PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PYPD news
Apr 15
4:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA), PolyPid (PYPD) and Eli Lilly & Co (LLY)
Feb 15
6:30am ET
Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), PolyPid (PYPD) and Nyxoah (NYXH)
Feb 15
6:16am ET
PolyPid price target lowered to $14 from $16 at H.C. Wainwright
Feb 14
11:55am ET
Buy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market Positioning
Feb 14
7:04am ET
PolyPid reports Q4 EPS ($3.97), consensus ($3.58)
Feb 12
7:12am ET
PolyPid enrolls 100th patient in SHIELD II phase 3 trial
Feb 01
5:28pm ET
PolyPid files to sell 6.74M ordinary shares for holders
Jan 29
5:07am ET
PolyPid (PYPD) Receives a Hold from Barclays
No recent press releases are available for PYPD
PYPD Financials
Key terms
Ad Feedback
PYPD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PYPD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
